Biotech Showdown: How to Choose Between ARKG, XBI, and IBB

Many friends ask me — they want to buy US biotech stocks but don't know which ETF to pick. They see ARKG, XBI, and IBB all labeled "biotech" and wonder how they actually differ. In short, these three ETFs represent three completely different ways to play the space — one is a scientist's dream, one is a gambler's chip, and one is a pension fund's anchor. 2026 is shaping up to be the year of the largest "Patent Cliff" in history, with more than $200 billion in branded-drug sales set to evaporate over the next five years. The fortunes of these three ETFs are about to diverge.

The Fundamental Differences Between the Three ETFs

ARKG (ARK Genomic Revolution ETF) is the most aggressive of the three, centered on the "genomic revolution" thesis. It picks small- and mid-cap names in CRISPR, sequencing, liquid-biopsy oncology, and AI-driven drug discovery.

As of mid-2026, ARKG manages roughly $1.73 billion in assets and holds just 40 to 60 stocks. Top holdings include Beam Therapeutics (gene editing, 4.34%), Guardant Health (liquid biopsy, 4.28%), Natera (non-invasive prenatal testing and oncology screening, 4.11%), and Illumina (the sequencing leader). Like other ARK products, this ETF is active, highly concentrated, charges no load fees but carries a relatively steep 0.75% expense ratio — designed to capture the alpha of disruptive innovation.

XBI (SPDR S&P Biotech ETF) is the exact opposite. It uses an equal-weighted structure to hold roughly 150 to 200 small- and mid-cap biotech names, with each stock averaging 0.3% to 0.5% of the portfolio. The upside of this design is that no single stock can drag down the entire ETF; the downside is that you will never lead a sector rally, but you also won't fall the hardest in a sell-off. XBI is the purest gauge of small- and mid-cap biotech R&D names, and is especially suited for tracking catalysts such as clinical-trial readouts and FDA approval decisions.

IBB (iShares Biotechnology ETF) is the old guard. It selects large- and mid-cap biotech companies that are already profitable and have products on the market. Top holdings are typically Amgen, Gilead, Vertex, Regeneron, and Bristol Myers Squibb — each with market caps exceeding $100 billion. IBB has a high correlation with the S&P 500 healthcare sector, lower volatility, and fits steady-handed investors looking for a core holding.

The Most Critical Macro Theme of 2026: The Patent Cliff

According to Fierce Pharma, beginning in 2026 a wave of blockbuster drugs will lose patent protection over four consecutive years. The biggest hits are Merck's Keytruda (pembrolizumab, US patent expiry 2028) and Bristol Myers Squibb's Eliquis (apixaban, facing the first generic challenge in November 2026). Eliquis alone generates more than $12 billion in annual global sales, making it the top seller in the anticoagulant market.

Other names on the high-risk list include Merck's Januvia/Janumet (diabetes, 2026), Novartis's Ilaris, BMS's Yervoy, and Eli Lilly's Cyramza. The Financial Times estimates that between 2027 and 2028 a combined roughly $180 billion in sales will be at risk — enough to reshuffle the entire pharma sector.

This trend affects the three ETFs very differently. IBB, with its heavy weighting in these soon-to-expire large pharma names, faces near-term revenue pressure. But at the same time, big pharma will use M&A — acquiring small- and mid-cap biotechs — to refill their pipelines. And the targets of those acquisitions are precisely the names sitting in XBI and ARKG. So the fates of the three ETFs are tied together: "IBB takes the short-term hit, while XBI and ARKG reap the long-term rewards."

Sector Catalysts: Weight-Loss Drugs, Gene Editing, and AI Drug Discovery

The biggest tailwind for biotech in 2026 is GLP-1 weight-loss drugs. Eli Lilly's Zepbound and Novo Nordisk's Wegovy continue to deliver blockbuster sales, and both are core IBB holdings. GLP-1's total annual sales are projected to surpass $150 billion by 2028 — enough to carry half of IBB on its own.

On the ARKG side, the 2024 Nobel Prize in Medicine was awarded to microRNA discoverers Victor Ambros and Gary Ruvkun, sparking a sharp rally in gene-regulation-related names. On the CRISPR therapy front, Casgevy — developed by Vertex and CRISPR Therapeutics — has received FDA approval to treat sickle cell disease and beta-thalassemia, marking the world's first commercial CRISPR therapy milestone. Beam Therapeutics' base-editing platform and Intellia Therapeutics' early in vivo gene-editing clinical data are both highly anticipated.

On the AI drug-discovery front, Recursion Pharmaceuticals has partnered with NVIDIA on the BioHive supercomputer to train AI models that identify novel drug targets — most of these names are ARKG holdings. OpenAI, Anthropic, and other large language model companies are rumored to have begun collaborating with pharma companies on drug development, and the first AI-designed molecules are expected to enter clinical trials between 2026 and 2027.

Risks and Volatility

ARKG's biggest risks are concentration and volatility. Its historical maximum drawdown has exceeded 79% (a 73% decline from 2020 to 2022). Although it has rebounded 45.43% YTD in 2026, that is the price of high beta. XBI's equal-weight design keeps volatility relatively tame, though it has also seen drawdowns above 40%. IBB has the lowest volatility, but because of its heavy weighting in mature big pharma, its alpha is limited — it's a market-following instrument.

Another hidden risk is FDA policy shifts. After the US Secretary of Health changed in early 2025, the FDA approval pace briefly slowed. Although it later returned to normal, the impact hit small- and mid-cap biotech names (XBI and ARKG's core holdings) hardest.

How to Allocate

If you're a thematic investor looking to bet on the long-term revolution in gene editing and AI drug discovery, ARKG is the most direct vehicle, but cap your position at under 5% of the portfolio and play it with a high risk appetite.

If you want event-driven returns from small- and mid-cap M&A, XBI is the best fit. Historically, big pharma has spent $100–200 billion a year on M&A at peak, and from 2026 to 2028 patent-cliff pressure will only intensify that activity. Whenever a mid-cap biotech gets acquired, the target stock held by XBI gets repriced immediately.

If you want steady exposure to biotech's beta (market-tracking), IBB is the traditional choice, suitable as a retirement portfolio or core holding.

A more aggressive approach is "XBI as core, ARKG as satellite" — use XBI's equal-weight structure to diversify risk and ARKG's concentration to chase the alpha of disruptive innovation. IBB can serve as a hedge against big pharma and macro-policy risk.

Conclusion

The question with these three ETFs isn't "which is better" — it's "what kind of money do you want to make?" 2026's patent cliff will be biotech's biggest reshuffle in a decade. As blockbusters like Keytruda and Eliquis lose exclusivity, hundreds of billions of dollars in R&D value will shift from big pharma to small- and mid-cap biotechs. Knowing which ETF to pick isn't just about choosing a tool — it's about choosing which story you want to be part of.

Risk Disclaimer: Biotech ETFs are highly volatile; past performance does not guarantee future returns. This article is for informational purposes only and is not investment advice. Investors must make their own judgment and assume all risks.